30. Januar 2024 | 31:57 mins.
Webinar Series
Your safe path through the contract jungle: CDAs, MTAs & Co. | Coffee Break Life Sciences Start-ups #1
Early stage IP strategy pays off – Our experts Dr. Anja Lunze, LL.M. & Tobias Baus explained the pros and cons of IP protection, how to build a custom IP strategy with a matching IP portfolio, and why early patent protection is essential for biotech & pharma start-ups.
Life science technologies will require a substantial amount of (external) financing to be successful. Our leading VC experts will help you navigate the funding process and avoid unnecessary pitfalls in negotiations with investors.
In dieser Serie
Coffee Break Life Sciences Start-ups | Overview page
Your safe path through the contract jungle: CDAs, MTAs & Co. | Coffee Break Life Sciences Start-ups #1
30. January 2024
Don’t forget: Early stage IP strategy | Coffee Break Life Sciences Start-ups #2
23. February 2024
Tips and tricks for your financing round | Coffee Break Life Sciences Start-ups #3
20. March 2024
R&D Collaborations | Coffee Break Life Sciences Start-ups #4
18. April 2024
Employment Law in a Nutshell | Coffee Break Life Sciences Start-ups #5
15. May 2024
von Dr. Jan W. Grawe
Consulting Agreements: Dos and Don’ts | Coffee Break Life Sciences Start-ups #6
26. June 2024
Clinical trials in the pharmaceutical area: tips and tricks for CTA negotiations | Coffee Break Life Sciences Start-ups #7
18. July 2024
Clinical trials in the medical devices area: tips and tricks for CTA negotiations | Coffee Break Life Sciences Start-ups #8
22. August 2024
Data Protection for Life Sciences start-ups, particularly in connection with clinical trials | Coffee Break Life Sciences Start-ups #9
27. September 2024
Think big – possible exit strategies | Coffee Break Life Sciences Start-ups #10
20. October 2024
Website, Social Media, Advertising & Co. | Coffee Break Life Sciences Start-ups #11
19. November 2024
Would you like to receive future invitations to our webinar series?
Then sign up for our mailing list.Related Insights
R&D Collaborations | Coffee Break Life Sciences Start-ups #4
Medical devices & the EU draft regulation on AI – new challenges for my business?
von mehreren Autoren
